Sign inJoin waitlistJoin the waitlist

Michael Overman

Professor of · University of Texas M D Anderson Cancer Center

Credentials: · · · ·

History

University of Texas M D Anderson Cancer Center
Present

Hematology and Medical Oncology
University of Texas M D Anderson Cancer Center
2004–2007
Internal Medicine
2000–2003
Johns Hopkins Univ Sch of Med
1996–2000

Research

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
The Lancet Oncology · 2017 · First of 16 authors · 2,298 citations
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Journal of Clinical Oncology · 2018 · First of 20 authors · 1,662 citations
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 1,286 citations

Scott Kopetz
133 papers
Kanwal Raghav
94 papers · 3 as a fellow
Robert Wolff
91 papers
Cathy Eng
56 papers
Van Morris
50 papers · 5 as a fellow
Arvind Dasari
47 papers
GV
Gauri Varadhachary
47 papers
Bryan Kee
41 papers
DF
David Fogelman
37 papers
Huamin Wang
36 papers
Dipen Maru
33 papers
Christine Parseghian
32 papers · 7 as a fellow

Grants

A Technological Approach for Performance Status Assessment in Advanced Cancer Patients
National Cancer Institute · R01
PI · $3M · University of Tx Md Anderson Can Ctr
2020–2026
MD Anderson Cancer Center SPORE in Gastrointestinal Cancer
National Cancer Institute · P50
Project lead · $1.2M · University of Tx Md Anderson Can Ctr
2019–2025
KRAS Muations in Plasma cfDNA as Predictor to Erolinib Response in Advanced Pancreatic Cancer
National Cancer Institute · R21
PI · $382.8K · University of Tx Md Anderson Can Ctr
2015–2018

Clinical trials

The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2024–2028
Pevonedistat and Pembrolizumab for the Treatment of dMMR/MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor
Principal investigator · Terminated · Phase 1, Phase 2
M.D. Anderson Cancer Center
2021–2022
Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2021–2027
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
Principal investigator · Recruiting · Phase 2
SWOG Cancer Research Network
2020–2027